Matching articles for "Penbraya"
Penmenvy — A Second Pentavalent Meningococcal Vaccine
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old.…
Med Lett Drugs Ther. 2025 Apr 14; 67(1726):57-9 doi:10.58347/tml.2025.1726a
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
Penbraya: A Pentavalent Meningococcal Vaccine
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or…
Med Lett Drugs Ther. 2024 Mar 18; 66(1698):43-5 doi:10.58347/tml.2024.1698b
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo , MenQuadfi ) and two meningococcal serogroup B vaccines (MenB; Bexsero , Trumenba ) are available in the US (see Table 2).
